Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 1

1(20.0%)

Early Phase 1

1(20.0%)

Phase 4

1(20.0%)

5Total

Phase 2(2)

Phase 1(1)

Early Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06794541Phase 2Recruiting

A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

Role: collaborator

NCT07568275Early Phase 1Active Not Recruiting

Comparison of Angiotensin II to Standard Dose Vasopressors on Change in Arterial Elastance

Role: collaborator

NCT07485010Phase 2Not Yet Recruiting

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

Role: collaborator

NCT06801223Phase 1Recruiting

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

Role: lead

NCT06746883Recruiting

A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection

Role: lead

NCT07212686Phase 4Enrolling By Invitation

Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension

Role: collaborator

All 6 trials loaded